| 1 |
Xiong J , Zhou X , Su L , Jiang L , Ming Z , Pang C , Fuller C , Xu K , Chi H , Zheng X . The two - sided battlefield of tumour - associated macrophages in glioblastoma: unravelling their therapeutic potential. Discov Oncol, 2024, 15: 590.
|
| 2 |
Obrador E , Moreno-Murciano P , Oriol-Caballo M , López-Blanch R , Pineda B , Gutiérrez-Arroyo JL , Loras A , Gonzalez-Bonet LG , Martinez - Cadenas C , Estrela JM , Marqués - Torrejón MÁ . Glioblastoma therapy: past, present and future. Int J Mol Sci, 2024, 25: 2529.
|
| 3 |
Pinson H , Hallaert G , Van der Meulen J , Dedeurwaerdere F , Vanhauwaert D , Van den Broecke C , Van Dorpe J , Van Roost D , Kalala JP , Boterberg T . Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. J Neurooncol, 2020, 146: 55- 62.
|
| 4 |
Mansouri A , Hachem LD , Mansouri S , Nassiri F , Laperriere NJ , Xia D , Lindeman NI , Wen PY , Chakravarti A , Mehta MP , Hegi ME , Stupp R , Aldape KD , Zadeh G . MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol, 2019, 21: 167- 178.
|
| 5 |
Hegi ME , Oppong FB , Perry JR , Wick W , Henriksson R , Laperriere NJ , Gorlia T , Malmström A , Weller M . No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE.6 and the pooled Nordic/NOA -08 trials in elderly glioblastoma patients. Neuro Oncol, 2024, 26: 1867- 1875.
|
| 6 |
Zhao K , Sun G , Wang Q , Xue Z , Liu G , Xia Y , Yao A , Zhao Y , You N , Yang C , Xu B . The diagnostic value of conventional MRI and CT features in the identification of the IDH1- mutant and 1p/19q co - deletion in WHO grade Ⅱ gliomas. Acad Radiol, 2021, 28: e189- e198.
|
| 7 |
Reifenberger G , Hentschel B , Felsberg J , Schackert G , Simon M , Schnell O , Westphal M , Wick W , Pietsch T , Loeffler M , Weller M , German Glioma Network . Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer, 2012, 131: 1342- 1350.
|
| 8 |
Louis DN , Perry A , Reifenberger G , von Deimling A , Figarella - Branger D , Cavenee WK , Ohgaki H , Wiestler OD , Kleihues P , Ellison DW . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016, 131: 803- 820.
|
| 9 |
Louis DN , Perry A , Wesseling P , Brat DJ , Cree IA , Figarella - Branger D , Hawkins C , Ng HK , Pfister SM , Reifenberger G , Soffietti R , von Deimling A , Ellison DW . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol, 2021, 23: 1231- 1251.
|
| 10 |
Liu X , Chen HY , Zou WJ , Li GL . Interpretation on the diagnostic molecular parameters in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition). Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21: 751- 763.
doi: 10.3969/j.issn.1672-6731.2021.09.005
|
|
刘幸, 陈慧媛, 邹婉婧, 李桂林. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)分子诊断指标解读. 中国现代神经疾病杂志, 2021, 21: 751- 763.
doi: 10.3969/j.issn.1672-6731.2021.09.005
|
| 11 |
Bady P , Delorenzi M , Hegi ME . Sensitivity analysis of the MGMT - STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. J Mol Diagn, 2016, 18: 350- 361.
|
| 12 |
Khalaj V , AghaAmiri S , Ghosh SC , Vargas SH , Momeny M , Azhdarinia A . A simple and rapid in vitro assay for identification of direct inhibitors of O6 - methylguanine - DNA methyltransferase. Biotechniques, 2024, 76: 343- 351.
|
| 13 |
Lucas CG , Al - Adli NN , Young JS , Gupta R , Morshed RA , Wu J , Ravindranathan A , Shai A , Oberheim Bush NA , Taylor JW , de Groot J , Villanueva - Meyer JE , Pekmezci M , Perry A , Bollen AW , Theodosopoulos PV , Aghi MK , Chang EF , Hervey - Jumper SL , Raleigh DR , Molinaro AM , Costello JF , Diaz AA , Clarke JL , Butowski NA , Phillips JJ , Chang SM , Berger MS , Solomon DA . Longitudinal multimodal profiling of IDH - wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol, 2025, 27: 89- 105.
|
| 14 |
Weller M , Tabatabai G , Kästner B , Felsberg J , Steinbach JP , Wick A , Schnell O , Hau P , Herrlinger U , Sabel MC , Wirsching HG , Ketter R , Bähr O , Platten M , Tonn JC , Schlegel U , Marosi C , Goldbrunner R , Stupp R , Homicsko K , Pichler J , Nikkhah G , Meixensberger J , Vajkoczy P , Kollias S , Hüsing J , Reifenberger G , Wick W , DIRECTOR Study Group . MGMT promoter methylation is a strong prognostic biomarker for benefit from dose - intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res, 2015, 21: 2057- 2064.
|
| 15 |
Wanis HA , Møller H , Ashkan K , Davies EA . Association of IDH 1 mutation and MGMT promoter methylation with clinicopathological parameters in an ethnically diverse population of adults with gliomas in England. Biomedicines, 2024, 12: 2732.
|
| 16 |
Ghimire P , Kamaludin A , Palau BF , Lavrador JP , Gullan R , Vergani F , Bhangoo R , Ashkan K . MGMT methylation and its prognostic significance in inoperable IDH -wildtype glioblastoma: the MGMT - GBM study. Acta Neurochir (Wien), 2024, 166: 394.
|
| 17 |
Romano A , Calabria LF , Tavanti F , Minniti G , Rossi - Espagnet MC , Coppola V , Pugliese S , Guida D , Francione G , Colonnese C , Fantozzi LM , Bozzao A . Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol, 2013, 23: 513- 520.
|
| 18 |
Choi YS , Ahn SS , Kim DW , Chang JH , Kang SG , Kim EH , Kim SH , Rim TH , Lee SK . Incremental prognostic value of ADC histogram analysis over MGMT promoter methylation status in patients with glioblastoma. Radiology, 2016, 281: 175- 184.
|
| 19 |
Drabycz S , Roldán G , de Robles P , Adler D , McIntyre JB , Magliocco AM , Cairncross JG , Mitchell JR . An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage, 2010, 49: 1398- 1405.
|
| 20 |
Kanas VG , Zacharaki EI , Thomas GA , Zinn PO , Megalooikonomou V , Colen RR . Learning MRI - based classification models for MGMT methylation status prediction in glioblastoma. Comput Methods Programs Biomed, 2017, 140: 249- 257.
|
| 21 |
Ahn SS , Shin NY , Chang JH , Kim SH , Kim EH , Kim DW , Lee SK . Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast - enhanced magnetic resonance and diffusion tensor imaging. J Neurosurg, 2014, 121: 367- 373.
|
| 22 |
Li - Chun Hsieh K , Chen CY , Lo CM . Quantitative glioma grading using transformed gray - scale invariant textures of MRI. Comput Biol Med, 2017, 83: 102- 108.
|
| 23 |
Koska İÖ , Koska Ç . Deep learning classification of MGMT status of glioblastomas using multiparametric MRI with a novel domain knowledge augmented mask fusion approach. Sci Rep, 2025, 15: 3273.
|
| 24 |
Liu Y , Zhu Z , Zhou J , Wang H , Yang H , Yin J , Wang Y , Li X , Chen F , Li Q , Jiang Z , Wu X , Ge D , Zhang Y , Zhang X , Zhang B . Radiomics prediction of MGMT promoter methylation in adult diffuse gliomas: a combination of structural MRI, DCE, and DTI. Front Neurol, 2025, 16: 1493666.
|
| 25 |
Li L , Xiao F , Wang S , Kuang S , Li Z , Zhong Y , Xu D , Cai Y , Li S , Chen J , Liu Y , Li J , Li H , Xu H . Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi - sequence MRI radiomics analysis. Sci Rep, 2024, 14: 16031.
|